Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells

HDAC inhibitors (HDACi) hold great potential as anticancer therapies due to their ability to regulate the acetylation of both histone and non-histone proteins, which is frequently disrupted in cancer and contributes to the development and advancement of the disease. Additionally, HDACi have been sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Drzewiecka, Małgorzata, Jaśniak, Dominika, Barszczewska-Pietraszek, Gabriela, Czarny, Piotr, Kobrzycka, Anna, Wieczorek, Marek, Radek, Maciej, Szemraj, Janusz, Skorski, Tomasz, Śliwiński, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532614/
https://www.ncbi.nlm.nih.gov/pubmed/37763083
http://dx.doi.org/10.3390/jpm13091315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532614/
https://www.ncbi.nlm.nih.gov/pubmed/37763083
http://dx.doi.org/10.3390/jpm13091315

Ejemplares similares